作者
Adrian Budhram, Elia Sechi, Eoin P Flanagan, Divyanshu Dubey, Anastasia Zekeridou, Shailee S Shah, Avi Gadoth, Elie Naddaf, Andrew McKeon, Sean J Pittock, Nicholas L Zalewski
发表日期
2021/6/1
期刊
Journal of Neurology, Neurosurgery & Psychiatry
卷号
92
期号
6
页码范围
645-654
出版商
BMJ Publishing Group Ltd
简介
Objective
To determine clinical manifestations, immunotherapy responsiveness and outcomes of glutamic acid decarboxylase-65 (GAD65) neurological autoimmunity.
Methods
We identified 323 Mayo Clinic patients with high-titre (>20 nmol/L in serum) GAD65 antibodies out of 380 514 submitted anti-GAD65 samples (2003–2018). Patients classified as having GAD65 neurological autoimmunity after chart review were analysed to determine disease manifestations, immunotherapy responsiveness and predictors of poor outcome (modified Rankin score >2).
Results
On review, 108 patients were classified as not having GAD65 neurological autoimmunity and 3 patients had no more likely alternative diagnoses but atypical presentations (hyperkinetic movement disorders). Of remaining 212 patients with GAD65 neurological autoimmunity, median age at symptom onset was 46 years (range: 5–83 years); 163/212 (77 …
学术搜索中的文章
A Budhram, E Sechi, EP Flanagan, D Dubey… - Journal of Neurology, Neurosurgery & Psychiatry, 2021